Sanofi and GlaxoSmithKline said Wednesday that they signed a statement of intent with Gavi, the Vaccine Alliance to make 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine available to the COVAX facility. Thomas Triomphe, global head of Sanofi Pasteur, said the deal "reflects our long-term commitment to global health and ensures our COVID-19 vaccines are affordable and accessible to those most at risk, everywhere in the world."
COVAX, which aims to deliver 2 billion doses of COVID-19 vaccines by the end of 2021, has already reached agreements with AstraZeneca and Novavax. Meanwhile, Sanofi and GlaxoSmithKline signed a $2.1-billion deal to supply the US with more than 100 million doses of their vaccine, with similar agreements also in place with the EU, Canada and the UK.
Sanofi and GlaxoSmithKline initiated a Phase I/II study of their vaccine in September, with the first results expected in early December. The companies noted that pending the trial's outcome, a Phase III study is scheduled to start before the end of the year, with requests for marketing approval beginning in the first half of 2021.
To read more Top Story articles, click here.